ConductScience.org, home
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
API referenceFor AI assistants

Trial · NCT01931839

Participant flow35

How many started, completed or left each group, period by period.

1 to 20 of 35

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDArm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h335
Overall StudySTARTEDArm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h178
Overall StudySTARTEDArm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h340
Overall StudySTARTEDArm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h176
Overall StudySTARTEDArm 5 Part A: Observational Cohort19
Overall StudySTARTEDArm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h55
Overall StudySTARTEDArm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h60
Overall StudyFull Analysis Set (As Randomized)Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h334
Overall StudyFull Analysis Set (As Randomized)Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h179
Overall StudyFull Analysis Set (As Randomized)Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h340
Overall StudyFull Analysis Set (As Randomized)Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h176
Overall StudyFull Analysis Set (As Randomized)Arm 5 Part A: Observational Cohort19
Overall StudyFull Analysis Set (As Randomized)Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h55
Overall StudyFull Analysis Set (As Randomized)Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h60
Overall StudySafety Analysis Set (As Dosed)Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h335
Overall StudySafety Analysis Set (As Dosed)Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h178
Overall StudySafety Analysis Set (As Dosed)Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h340
Overall StudySafety Analysis Set (As Dosed)Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h176
Overall StudySafety Analysis Set (As Dosed)Arm 5 Part A: Observational Cohort19
Overall StudySafety Analysis Set (As Dosed)Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h55

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01931839/flow

API referenceFor AI assistants